Latest From FibroGen Inc.
Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.
China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.
AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in its battles with Jardiance and Invokana.
We might only be halfway through 2019, but In Vivo is taking in the long view and exploring some of the market-altering new drugs on the horizon that are expected to win approval and experience first launches at the opening of the next decade.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Hepatic (Liver)
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- North America
- Parent & Subsidiaries
- FibroGen Inc.
- Senior Management
Thomas B Neff, Chmn. & CEO
Pat Cotroneo, VP, Fin. & CFO
David M Dimmick, MD, VP, Quality
R. Wayne Frost, VP, RA
Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
AI Lin, MD, PhD, VP, Drug Dev.
Peony K Yu, CMO
- Contact Info
Phone: (415) 978-1200
409 Illinois St.
San Francisco, CA 94158
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.